European Clinics in Obstetrics and Gynaecology vol:1 issue:3 pages:143-150
Therapeutic options for cervical cancer have improved extensively over the last decade with the introduction of neoadjuvant chemotherapy prior to surgery for stage IB2–IIB and chemoradiation (radiation with concomitant weekly cisplatinum). Both regimens showed an improvement in overall survival of 14 and 12%, respectively, in comparison with radiotherapy alone. As for metastatic or recurrent cervical cancer, chemotherapy regimens are changing from cisplatin only to combination chemotherapy. Cisplatin with topotecan is the first combination regimen that showed an improvement in overall survival. However, further randomized trials will be necessary to confirm the superiority of this combination.